The myxobacterial metabolite Soraphen A inhibits HIV-1 by reducing virus production and altering virion composition.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Fleta-Soriano, EricSmutná, Katarína
Martinez, Javier P
Lorca Oró, Cristina
Sadiq, S Kashif
Mirambeau, Gilles
Lopez-Iglesias, Carmen
Bosch, Marta
Pol, Albert
Brönstrup, Mark
Diez, Juana
Meyerhans, Andreas
Issue Date
2017-05-22
Metadata
Show full item recordAbstract
Soraphen A is a myxobacterial metabolite that blocks the acetyl-CoA carboxylase of the host, and was previously identified as a novel HIV inhibitor. Here we report that Soraphen A acts by reducing virus production and altering the gp120 virion content, impacting entry capacity and infectivity. These effects are partially reversed by addition of palmitic acid, suggesting inhibition of HIV Env palmitoylation as one of the mechanisms of antiviral action.Citation
The myxobacterial metabolite Soraphen A inhibits HIV-1 by reducing virus production and altering virion composition. 2017 Antimicrob. Agents Chemother.Affiliation
Helmholtz Centre of infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.PubMed ID
28533249Type
ArticleLanguage
enISSN
1098-6596ae974a485f413a2113503eed53cd6c53
10.1128/AAC.00739-17
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
- Authors: Curreli F, Haque K, Xie L, Qiu Q, Xu J, Yong W, Tong X, Debnath AK
- Issue date: 2015 Dec 15
- Inhibition of HIV-1 entry: multiple keys to close the door.
- Authors: Hertje M, Zhou M, Dietrich U
- Issue date: 2010 Nov 8
- Blocking HIV-1 entry by a gp120 surface binding inhibitor.
- Authors: Tsou LK, Chen CH, Dutschman GE, Cheng YC, Hamilton AD
- Issue date: 2012 May 1
- Azasugar-containing phosphorothioate oligonucleotide (AZPSON) DBM-2198 inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking HIV-1 gp120 without affecting the V3 region.
- Authors: Lee J, Byeon SE, Jung JY, Kang MH, Park YJ, Jung KE, Bae YS
- Issue date: 2015
- Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
- Authors: Koutsoudakis G, Romero-Brey I, Berger C, Pérez-Vilaró G, Monteiro Perin P, Vondran FW, Kalesse M, Harmrolfs K, Müller R, Martinez JP, Pietschmann T, Bartenschlager R, Brönstrup M, Meyerhans A, Díez J
- Issue date: 2015 Oct